ClinicalTrials.gg
CompletedNCT00952289Updated Mar 12, 2018Results posted

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

A Phase 3 interventional study of Ruxolitinib and Placebo in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation. Completed at 112 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-12.

Primary conditionPrimary MyelofibrosisRegistry: Myeloproliferative DisordersReclassifiedWhy we changed it
Registry
Myeloproliferative Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Primary Myelofibrosis
Why
  1. The study's title name Primary Myelofibrosis, a narrower term within Myeloproliferative Disorders.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
3rd of 50
309 · median 45
Started
2009
with 1 other
Phase 3
6 of 50
none open now
Registered
3rd of 50
by date
Lead sponsor
5 of 50
Incyte Corporation

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 3rd largest by enrollment, is one of 2 that started in 2009, is one of 6 in phase 3, and was the 3rd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib (INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis (either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Read the detailed description

Patients with spleen growth of greater than 25% based on an increase in spleen volume from Baseline were eligible for early unblinding, and for patients on placebo, cross over to ruxolitinib prior to the primary study endpoint being reached. If this spleen growth occurred before Week 24, it must have been accompanied by specific worsening of symptoms, based on worsening early satiety accompanied by weight loss or worsening pain requiring daily narcotic use. After Week 24, asymptomatic spleen growth alone was sufficient for early unblinding and potential cross over. Patients found to have been randomized to ruxolitinib after early unblinding prior to Week 24 were discontinued.

When half of the patients remaining in the study completed the Week 36 visit and all patients enrolled completed Week 24 or discontinued, the database was frozen and the primary analysis was conducted. Once this was complete, all patients were unblinded and patients who had been randomized to placebo were given the opportunity to cross over to ruxolitinib treatment, provided hematology laboratory parameters were adequate; Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).

03

Conditions studied

  • MPN (Myeloproliferative Neoplasms)

Browse trials for

Keywords

  • Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis
04

In context

Primary Myelofibrosis Reclassified

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

This study's enrollment of 309 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.

Browse Primary Myelofibrosis studies →

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Compared within Primary Myelofibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myeloproliferative Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be diagnosed with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF) according to the 2008 World Health Organization criteria
  • Subjects with myelofibrosis requiring therapy must be classified as high risk OR intermediate risk level 2 according to the prognostic factors defined by the International Working Group
  • Subjects with an (ECOG) performance status of 0, 1, 2 or 3
  • Subjects who have not previously received treatment with a Janus kinase (JAK) inhibitor

Exclusion criteria

Exclusion Criteria:

  • Subjects with a of less than 6 months
  • Subjects with inadequate bone marrow reserve as demonstrated by specific clinical laboratory counts
  • Subjects with inadequate liver or renal function
  • Subjects with bacterial, fungal, parasitic or viral infection which require therapy
  • Subjects with an active over the previous 5 years except specific skin cancers.
  • Subjects with severe cardiac conditions
  • Subjects who have had splenic irradiation within 12 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count \> 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).

    Drug: Ruxolitinib

  • Placebo comparator
    Placebo

    Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.

    Drug: Ruxolitinib · Drug: Placebo

Interventions

  • Ruxolitinib phosphate tablets 5 mg administered as oral doses.

    Also known as: INCB018424

  • DrugPlacebo

    Matching placebo tablets were administered as oral doses in the same manner as active drug.

07

What researchers measure

Primary outcomes

  1. Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24

    Spleen volume was assessed by magnetic resonance imaging (MRI) or by computed tomography (CT) scans if MRI was not suitable, and analyzed by a blinded central laboratory reader. Patients who withdrew, crossed over to ruxolitinib prior to the visit, or had a missing value at the visit were considered non-responders.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib

    The maintenance of ≥ 35% reduction from Baseline in spleen volume was assessed up until the data cutoff date using the Kaplan-Meier method for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or who subsequently dropped out prior to another assessment.

    Time frame: Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).

  2. Duration of Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib

    The duration of ≥ 35% reduction from Baseline in spleen volume was defined as the longest duration of consecutive measurements of ≥ 35% reduction observed before the data cut-off date for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or, who subsequently dropped out prior to another assessment. The duration of a ≥ 35% reduction from Baseline in spleen volume was analyzed using the Kaplan-Meier method.

    Time frame: Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).

  3. Number of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 24

    Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.

    Time frame: Baseline and Week 24. Baseline total score was the average of the daily total scores for the last 7 days prior to randomization. The Week 24 total score was the average of daily total scores from the 28 days prior to the Week 24 visit.

  4. Change From Baseline to Week 24 in Total Symptom Score

    Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms hence a negative change from baseline indicates improvement.

    Time frame: Baseline and Week 24. Baseline total score was the average of the daily total scores for the last 7 days prior to randomization. The Week 24 total score was the average of daily total scores from the 28 days prior to the Week 24 visit.

  5. Overall Survival

    Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.

    Time frame: From randomization to the data cut-off date (up to 14 months).

  6. Overall Survival Time

    Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.

    Time frame: From randomization to the data cut-off date (up to 14 months).

  7. Overall Survival - Extended Data

    Overall survival is reported here by the number of deaths from randomization until 01 March 2011. Patients were censored at this time or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method. This outcome reports data from August 2009 through March 2011 to coincide with a pre-planned New Drug Application (NDA) 120-day safety update.

    Time frame: From randomization to 4 months after the data cut-off date (up to 18 months).

  8. Overall Survival Time - Extended Data

    Overall survival was assessed by the time to death or censoring up until 01 March 2011. Patients were censored at this time or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method. This outcome reports data from August 2009 through March 2011 to coincide with a pre-planned New Drug Application (NDA) 120-day safety update.

    Time frame: From randomization to 4 months after the data cut-off date (up to 18 months).

  9. Overall Survival at Week 144

    Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.

    Time frame: Week 144

  10. Overall Survival Time at Week 144

    Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.

    Time frame: Week 144

08

Results

Posted Jan 24, 2012

Participant flow

All Participants
Participant flow — All Participants
MilestoneRuxolitinibPlacebo
Started155154
Safety population155151
Completed134114
Not completed2140
Withdrew: Death99
Withdrew: Adverse event88
Withdrew: Disease progression312
Withdrew: Withdrawal by subject110
Withdrew: Data lost during site relocation01
Patients Who Crossed Over to Ruxolitinib
Participant flow — Patients Who Crossed Over to Ruxolitinib
MilestoneRuxolitinibPlacebo
Started0111
Completed057
Not completed054
Withdrew: Adverse event019
Withdrew: Disease progression015
Withdrew: Withdrawal by subject011
Withdrew: Non-compliance to study medication02
Withdrew: Other unspecified07

Outcome measures

PrimaryNumber of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24

Spleen volume was assessed by magnetic resonance imaging (MRI) or by computed tomography (CT) scans if MRI was not suitable, and analyzed by a blinded central laboratory reader. Patients who withdrew, crossed over to ruxolitinib prior to the visit, or had a missing value at the visit were considered non-responders.

Time frame:
Baseline and Week 24
Reported as:
Number · participants
Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24
participantsRuxolitinibPlacebo
Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24651
Statistical analysis
  • Ruxolitinib vs Placebo · Fisher Exact · p = <0.0001
SecondaryMaintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib

The maintenance of ≥ 35% reduction from Baseline in spleen volume was assessed up until the data cutoff date using the Kaplan-Meier method for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or who subsequently dropped out prior to another assessment.

Time frame:
Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).
Reported as:
Number · proportion of participants
Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib
proportion of participantsRuxolitinib
Still Responder by 48 weeks0.76 (0.66 to 0.84)
Still Responder by 96 weeks0.67 (0.55 to 0.76)
Still Responder by 144 weeks0.27 (0.02 to 0.63)
SecondaryDuration of Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib

The duration of ≥ 35% reduction from Baseline in spleen volume was defined as the longest duration of consecutive measurements of ≥ 35% reduction observed before the data cut-off date for patients who had at least one measured ≥ 35% reduction, and who either had at least one subsequent measurement or, who subsequently dropped out prior to another assessment. The duration of a ≥ 35% reduction from Baseline in spleen volume was analyzed using the Kaplan-Meier method.

Time frame:
Baseline Visit and every 12 weeks until the data cut-off date (up to 14 months).
Reported as:
Median · weeks
Duration of Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib
weeksRuxolitinib
Duration of Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib135.0 (107.6 to NA)
SecondaryNumber of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 24

Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.

Time frame:
Baseline and Week 24. Baseline total score was the average of the daily total scores for the last 7 days prior to randomization. The Week 24 total score was the average of daily total scores from the 28 days prior to the Week 24 visit.
Reported as:
Number · participants
Number of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 24
participantsRuxolitinibPlacebo
Number of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 24688
SecondaryChange From Baseline to Week 24 in Total Symptom Score

Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms hence a negative change from baseline indicates improvement.

Time frame:
Baseline and Week 24. Baseline total score was the average of the daily total scores for the last 7 days prior to randomization. The Week 24 total score was the average of daily total scores from the 28 days prior to the Week 24 visit.
Reported as:
Mean · scores on a scale
Change From Baseline to Week 24 in Total Symptom Score
scores on a scaleRuxolitinibPlacebo
Baseline18.0 ± 10.916.5 ± 11.5
Week 249.4 ± 9.719.7 ± 13.7
Change from Baseline-8.6 ± 10.03.2 ± 9.4
SecondaryOverall Survival

Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.

Time frame:
From randomization to the data cut-off date (up to 14 months).
Reported as:
Number · participants
Overall Survival
participantsRuxolitinibPlacebo
Death events1014
Censored events145140
SecondaryOverall Survival Time

Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.

Time frame:
From randomization to the data cut-off date (up to 14 months).
Reported as:
Median · weeks
Overall Survival Time
weeksRuxolitinibPlacebo
Overall Survival TimeNA (NA to NA)NA (NA to NA)
SecondaryOverall Survival - Extended Data

Overall survival is reported here by the number of deaths from randomization until 01 March 2011. Patients were censored at this time or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method. This outcome reports data from August 2009 through March 2011 to coincide with a pre-planned New Drug Application (NDA) 120-day safety update.

Time frame:
From randomization to 4 months after the data cut-off date (up to 18 months).
Reported as:
Number · participants
Overall Survival - Extended Data
participantsRuxolitinibPlacebo
Death events1324
Censored events142130
SecondaryOverall Survival Time - Extended Data

Overall survival was assessed by the time to death or censoring up until 01 March 2011. Patients were censored at this time or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method. This outcome reports data from August 2009 through March 2011 to coincide with a pre-planned New Drug Application (NDA) 120-day safety update.

Time frame:
From randomization to 4 months after the data cut-off date (up to 18 months).
Reported as:
Median · weeks
Overall Survival Time - Extended Data
weeksRuxolitinibPlacebo
Overall Survival Time - Extended DataNA (NA to NA)NA (NA to NA)
SecondaryOverall Survival at Week 144

Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.

Time frame:
Week 144
Reported as:
Number · participants
Overall Survival at Week 144
participantsRuxolitinibPlacebo
Death events4254
Censored events113100
SecondaryOverall Survival Time at Week 144

Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.

Time frame:
Week 144
Reported as:
Number · probability
Overall Survival Time at Week 144
probabilityRuxolitinibPlacebo
Overall Survival Time at Week 1440.74 (0.66 to 0.81)0.61 (0.53 to 0.69)

Adverse events

Collected over From randomization through data cut-off of the primary analysis (02 November 2010).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib—43/155 (27.7%)150/155 (96.8%)
Placebo—53/151 (35.1%)147/151 (97.4%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventRuxolitinibPlacebo
PneumoniaInfections and infestations10/1555/151
Abdominal painGastrointestinal disorders0/1556/151
AnaemiaBlood and lymphatic system disorders5/1553/151
Splenic infarctionBlood and lymphatic system disorders1/1554/151
FatigueGeneral disorders4/1550/151
Cardiac failure congestiveCardiac disorders1/1553/151
Disease progressionGeneral disorders0/1553/151
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/1553/151
ColitisGastrointestinal disorders1/1553/151
ThrombocytopeniaBlood and lymphatic system disorders3/1551/151
Most frequent other events
Showing 10 of 53
Most frequent other events
EventRuxolitinibPlacebo
Abdominal painGastrointestinal disorders16/15558/151
FatigueGeneral disorders38/15551/151
ThrombocytopeniaBlood and lymphatic system disorders52/15514/151
AnaemiaBlood and lymphatic system disorders45/15520/151
DiarrhoeaGastrointestinal disorders36/15532/151
Oedema peripheralGeneral disorders29/15534/151
NauseaGastrointestinal disorders22/15529/151
EcchymosisSkin and subcutaneous tissue disorders29/15514/151
DyspnoeaRespiratory, thoracic and mediastinal disorders26/15525/151
PruritusSkin and subcutaneous tissue disorders7/15523/151

Baseline characteristics

Age, Continuous
Age, Continuous(years)RuxolitinibPlaceboTotal
Mean66.7 ± 8.8268.7 ± 8.6667.7 ± 8.78
Sex/Gender, Customized
Sex/Gender, Customized(participants)RuxolitinibPlaceboTotal
Female7665141
Male7988167
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RuxolitinibPlaceboTotal
Black or African American6713
White138139277
Asian549
Native Hawaiian or Other Pacific Islander101
Other538
Disease Subtype
Disease Subtype(participants)RuxolitinibPlaceboTotal
Primary myelofibrosis7084154
Post-polycythemia vera-myelofibrosis504797
Post-essential thrombocythemia-myelofibrosis352257
Missing011
Spleen volume
Spleen volume(cm˄3)RuxolitinibPlaceboTotal
Mean2745.7 ± 1247.02797.6 ± 1388.52771.5 ± 1317.3
JAK2 V617F Mutation Status
JAK2 V617F Mutation Status(participants)RuxolitinibPlaceboTotal
Positive113123236
Negative402767
Unknown/Missing246
09

Study locations

112 sites
  • Birmingham, Alabama, United States
  • Scottsdale, Arizona, United States
  • Baldwin Park, California, United States
  • Bellflower, California, United States
  • Beverly Hills, California, United States
  • Corona, California, United States
  • Fullerton, California, United States
  • Highland, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • Palo Alto, California, United States
  • Panorama City, California, United States
  • Rancho Cucamonga, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • West Covina, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • Fort Collins, Colorado, United States
  • Norwalk, Connecticut, United States
  • Washington, District of Columbia, United States
  • Boynton Beach, Florida, United States
  • Gainesville, Florida, United States
  • Jacksonville, Florida, United States
  • West Palm Beach, Florida, United States
  • Winter Park, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Honolulu, Hawaii, United States
  • Boise, Idaho, United States
  • Meridian, Idaho, United States
  • Twin Falls, Idaho, United States
  • Chicago, Illinois, United States
  • Beech Grove, Indiana, United States
  • Indianapolis, Indiana, United States
  • Ames, Iowa, United States
  • Iowa City, Iowa, United States
  • Sioux City, Iowa, United States
  • Waterloo, Iowa, United States
  • Louisville, Kentucky, United States
  • Alexandria, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Novi, Michigan, United States
  • Southfield, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Rochester, Minnesota, United States
  • Saint Louis Park, Minnesota, United States
  • New Albany, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Billings, Montana, United States
  • Denville, New Jersey, United States
  • Hackensack, New Jersey, United States
  • Morristown, New Jersey, United States
  • Somerville, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • East Setauket, New York, United States
  • New York, New York, United States
  • Valhalla, New York, United States
  • Durham, North Carolina, United States
  • Hickory, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Bismarck, North Dakota, United States
  • Akron, Ohio, United States
  • Canton, Ohio, United States
  • Cleveland, Ohio, United States
  • Dayton, Ohio, United States
  • Dover, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Germantown, Tennessee, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • New Braunfels, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Burlington, Vermont, United States
  • Everett, Washington, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Darlinghurst, New South Wales, Australia
  • Kogarah, New South Wales, Australia
  • Randwick, New South Wales, Australia
  • St Leonards, New South Wales, Australia
  • Brisbane, Queensland, Australia
  • Douglas, Queensland, Australia
  • Herston, Queensland, Australia
  • Milton, Queensland, Australia
  • Woolloongabba, Queensland, Australia
  • Bedford Park, South Australia, Australia
  • Box Hill, Victoria, Australia
  • Clayton, Victoria, Australia

Showing the first 100 of 112 sites across 3 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Verstovsek S, Mesa R, Gotlib J, et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK1/2 inhibitor INCB18424 (424) vs placebo (PB) for patients with myelofibrosis (MF). The 47th Annual ASCO meeting, Chicago, IL. J Clin Oncol 2011; 29 (suppl; abstract 6500). Verstovsek S, Mesa R, Gotlib J, et al. Results of COMFORT-I, a randomized, double-blind phase III trial of the JAK1 and JAK2 inhibitor ruxolitinib (INCB018424) versus placebo for patients with myelofibrosis. The 16th Annual EHA meeting, London, UK. Haematologica 2011; 96 (suppl 2; abstract 0505).
  • Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. PubMed 22375971 ↗
  • Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec;98(12):1865-71. doi: 10.3324/haematol.2013.092155. Epub 2013 Sep 13. PubMed 24038026 ↗
  • Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23. PubMed 25616577 ↗
  • Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017 Sep 29;10(1):156. doi: 10.1186/s13045-017-0527-7. PubMed 28962635 ↗
  • Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):479-487. doi: 10.1016/j.clml.2017.05.015. Epub 2017 May 12. PubMed 28606598 ↗
  • Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z. PubMed 28228106 ↗
  • Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015 Sep 24;126(13):1551-4. doi: 10.1182/blood-2015-03-635235. Epub 2015 Jul 30. PubMed 26228487 ↗
  • Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. PubMed 26069290 ↗
  • Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):214-221.e1. doi: 10.1016/j.clml.2014.12.008. Epub 2014 Dec 27. PubMed 25682576 ↗
  • Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014 Feb;99(2):292-8. doi: 10.3324/haematol.2013.087650. Epub 2013 Aug 2. PubMed 23911705 ↗
  • Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013 Apr 1;31(10):1285-92. doi: 10.1200/JCO.2012.44.4489. Epub 2013 Feb 19. PubMed 23423753 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Nov 2010 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 2 months after primary completion. A results delay was requested in Jun 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2009
First posted
Aug 6, 2009
Start
Aug 2009
Primary completionActual
Nov 2010
CompletionActual
Oct 2015
Results delay requested
Jun 18, 2010
Results first posted
Jan 24, 2012
Last update
Mar 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00952289
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 6, 2009
Start date
Aug 2009
Primary completion
Nov 2010
Completion
Oct 2015
Results posted
Jan 24, 2012
Last update
Mar 12, 2018

Study contacts

Srdan Verstovsek, MD, PhD
study director · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion